310 related articles for article (PubMed ID: 24673727)
1. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
Hamed RH; Anter AH; Awad IA
Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
[TBL] [Abstract][Full Text] [Related]
4. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
[TBL] [Abstract][Full Text] [Related]
5. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
8. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
9. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
12. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
Anselmo AP; Cavalieri E; Osti FM; Cantonetti M; De Sanctis V; Alfo M; Amadori S; Enrici RM
Anticancer Res; 2004; 24(6):4045-50. PubMed ID: 15736450
[TBL] [Abstract][Full Text] [Related]
13. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
14. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
Ogura M; Itoh K; Kinoshita T; Fukuda H; Takenaka T; Ohtsu T; Kagami Y; Tobinai K; Okamoto M; Asaoku H; Sasaki T; Mikuni C; Hirano M; Chou T; Ohnishi K; Ohno H; Nasu K; Okabe K; Ikeda S; Nakamura S; Hotta T; Shimoyama M
Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
Filatova LV; Plotnikova AA; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2013; 59(2):59-65. PubMed ID: 23814851
[TBL] [Abstract][Full Text] [Related]
17. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
18. [ABVD chemotherapy for Hodgkin lymphoma at a single institute].
Ohshima R; Motomura S; Hashimoto C; Miyazaki T; Ito S; Takasaki H; Hyo R; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Tomita N; Fujita H; Fujisawa S; Harano H; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2010 Dec; 51(12):1756-61. PubMed ID: 21258185
[TBL] [Abstract][Full Text] [Related]
19. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
20. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
